Visterra acquires license for dengue antibodies Vaccine News Daily Visterra, Inc., an antibody therapeutics developer, announced on Monday that it secured an exclusive patent license to a family of early-stage monoclonal antibodies that target dengue virus. The antibodies were developed by the Massachusetts Institute ... |
